Publications by authors named "Isma Rana"

Claim this Profile
C
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
Susanna Slater, Annette Bryant, Hsiang-Chi Chen, Ruwaida Begum, Isma Rana

BMC Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy.
David K Lau, Maria Aresu, Timothy Planche, Amina Tran, Retchel Lazaro-Alcausi, Isma Rana

Oncologist· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study.
Fiona Turkes, Annette Bryant, Ruwaida Begum, Michael Davidson, Eleftheria Kalaitzaki, Isma Rana

Curr Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.
Shelize Khakoo, Paul David Carter, Gina Brown, Nicola Valeri, Simona Picchia, Isma Rana

Clin Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme.
Michael Davidson, Lauren I Aronson, Julie Howard-Reeves, Hanna Bryant, Rosalind J Cutts, Isma Rana

Eur J Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial.
Gayathri Anandappa, Andrea Lampis, David Cunningham, Khurum H Khan, Kyriakos Kouvelakis, Isma Rana

Clin Cancer Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
Andrew Woolston, Khurum Khan, Georgia Spain, Louise J Barber, Beatrice Griffiths, Isma Rana

Cancer Cell· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma.
Michael Davidson, Louise J Barber, Andrew Woolston, Catherine Cafferkey, Sonia Mansukhani, Isma Rana

Cancers (Basel)· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
Sonia Mansukhani, Louise J Barber, Dimitrios Kleftogiannis, Sing Yu Moorcraft, Michael Davidson, Isma Rana

Clin Chem· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.
Khurum Khan, Mihaela Rata, David Cunningham, Dow-Mu Koh, Nina Tunariu, Isma Rana

Gut· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis